Abstract
Patients with peanut allergy (PA) may undergo oral immunotherapy (OIT). Currently, there are only a few biomarkers that reflect the progress of immune modulation. Pathogenic TH2A cells, a unique TH2 cell subset, have been shown to parallel clinical allergy. This pilot study evaluates changes of TH2A and other T cell subsets as biomarkers in patients undergoing peanut OIT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
